NO974569L - Benzamider for behandling av neurodegenerative forstyrrelser - Google Patents

Benzamider for behandling av neurodegenerative forstyrrelser

Info

Publication number
NO974569L
NO974569L NO974569A NO974569A NO974569L NO 974569 L NO974569 L NO 974569L NO 974569 A NO974569 A NO 974569A NO 974569 A NO974569 A NO 974569A NO 974569 L NO974569 L NO 974569L
Authority
NO
Norway
Prior art keywords
benzamides
treatment
neurodegenerative disorders
neurodegenerative
disorders
Prior art date
Application number
NO974569A
Other languages
English (en)
Other versions
NO318441B1 (no
NO974569D0 (no
Inventor
William David Flitter
William A Garland
Allan L Wilcox
Richard E Paylor
Original Assignee
Centaur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/415,847 external-priority patent/US5643965A/en
Priority claimed from US08/415,248 external-priority patent/US5659082A/en
Priority claimed from US08/415,694 external-priority patent/US5658953A/en
Application filed by Centaur Pharmaceuticals Inc filed Critical Centaur Pharmaceuticals Inc
Publication of NO974569D0 publication Critical patent/NO974569D0/no
Publication of NO974569L publication Critical patent/NO974569L/no
Publication of NO318441B1 publication Critical patent/NO318441B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19974569A 1995-04-03 1997-10-02 Benzamider og preparater som inbefatter slike for behandling av neurodegenerative forstyrrelser NO318441B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41567795A 1995-04-03 1995-04-03
US08/415,847 US5643965A (en) 1995-04-03 1995-04-03 Aminobenzamide compounds for the treatment of neurodegenerative disorders
US08/415,248 US5659082A (en) 1995-04-03 1995-04-03 Nitro- and aminobenzamide compounds for neurodegenerative disorders
US08/415,694 US5658953A (en) 1995-04-03 1995-04-03 Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders
PCT/US1996/004538 WO1996031462A1 (en) 1995-04-03 1996-04-03 Benzamides for neurodegenerative disorder treatment

Publications (3)

Publication Number Publication Date
NO974569D0 NO974569D0 (no) 1997-10-02
NO974569L true NO974569L (no) 1997-11-21
NO318441B1 NO318441B1 (no) 2005-03-21

Family

ID=27503636

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974569A NO318441B1 (no) 1995-04-03 1997-10-02 Benzamider og preparater som inbefatter slike for behandling av neurodegenerative forstyrrelser

Country Status (38)

Country Link
EP (1) EP0819113B1 (no)
JP (1) JP3479658B2 (no)
KR (1) KR100429120B1 (no)
CN (1) CN1073552C (no)
AR (1) AR002978A1 (no)
AT (1) ATE202552T1 (no)
AU (1) AU721045B2 (no)
BG (1) BG63384B1 (no)
CA (1) CA2215166A1 (no)
CO (1) CO4700431A1 (no)
CZ (1) CZ295852B6 (no)
DE (1) DE69613567T2 (no)
DK (1) DK0819113T3 (no)
DZ (1) DZ2012A1 (no)
EA (1) EA002031B1 (no)
EE (1) EE03437B1 (no)
ES (1) ES2160240T3 (no)
GR (1) GR3036466T3 (no)
HR (1) HRP960156B1 (no)
HU (1) HUP9801759A3 (no)
IL (1) IL117629A (no)
IS (1) IS1919B (no)
MA (1) MA23837A1 (no)
MX (1) MX9707596A (no)
MY (1) MY121206A (no)
NO (1) NO318441B1 (no)
NZ (1) NZ306204A (no)
PL (1) PL184121B1 (no)
PT (1) PT819113E (no)
RO (1) RO116190B1 (no)
SA (1) SA96160739B1 (no)
SI (1) SI0819113T1 (no)
SK (1) SK282900B6 (no)
TN (1) TNSN96051A1 (no)
TR (1) TR199701114T1 (no)
TW (1) TW381073B (no)
WO (1) WO1996031462A1 (no)
YU (1) YU21096A (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252403A1 (en) * 1996-04-17 1997-10-23 William Garland Benzamide treatment of dementia associated with aids virus (hiv-1) infection
DE69828197T2 (de) * 1997-10-27 2005-12-08 Sumitomo Pharmaceuticals Co., Ltd. Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
EP1079820A1 (en) 1998-05-19 2001-03-07 Centaur Pharmaceuticals, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
AU3985699A (en) * 1998-05-19 1999-12-06 Centaur Pharmaceuticals, Inc. Amide therapeutics for the treatment of inflammatory bowel disease
WO2000064430A1 (en) * 1999-04-23 2000-11-02 Sumitomo Pharmaceuticals Co., Ltd. Apoptosis inhibitors
CN101817761B (zh) * 2010-01-29 2014-06-25 浙江大学 苯甲酸酯类衍生物及制备方法和应用
EP2535059A4 (en) * 2010-02-10 2014-03-12 Public Univ Corp Yokohama City USE OF A MSIN3B BINDING COMPOUND FOR SPECIFIC BINDING TO THE NEURONIC RESTRICTIVE SILENCER FACTOR (NRSF)
WO2014155184A1 (en) * 2013-03-28 2014-10-02 Rhenovia Pharma Treatment for parkinson's disease
CN115594603A (zh) * 2022-10-09 2023-01-13 湖北师范大学(Cn) 微通道反应器制备n-叔丁基-4-氨基苯甲酰胺的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1069882B (it) * 1975-12-22 1985-03-25 Mallinckrodt Inc 3 5 bis acilammino benzammidi particolarmente utili come agenti di contrasto per raffi x e procedimento per la loro preparazione
JPS5721320A (en) * 1980-07-11 1982-02-04 Chugai Pharmaceut Co Ltd Blood sugar level depressing agent
JPS5867657A (ja) * 1981-10-15 1983-04-22 Chugai Pharmaceut Co Ltd ペンズアミド誘導体
US5472983A (en) * 1994-04-14 1995-12-05 Centaur Pharmaceuticals, Inc. Benzamide-containing pharmaceutical compositions

Also Published As

Publication number Publication date
WO1996031462A1 (en) 1996-10-10
NZ306204A (en) 1999-01-28
MY121206A (en) 2006-01-28
AU5440496A (en) 1996-10-23
IS4569A (is) 1997-09-25
TR199701114T1 (xx) 1998-02-21
NO318441B1 (no) 2005-03-21
AR002978A1 (es) 1998-05-27
KR100429120B1 (ko) 2004-08-18
DK0819113T3 (da) 2001-10-15
PL322625A1 (en) 1998-02-02
EP0819113A1 (en) 1998-01-21
CN1182416A (zh) 1998-05-20
HUP9801759A3 (en) 2001-06-28
CZ295852B6 (cs) 2005-11-16
TNSN96051A1 (fr) 2005-03-15
SI0819113T1 (en) 2001-10-31
JPH11501319A (ja) 1999-02-02
EA002031B1 (ru) 2001-12-24
JP3479658B2 (ja) 2003-12-15
HUP9801759A2 (hu) 1998-12-28
RO116190B1 (ro) 2000-11-30
CN1073552C (zh) 2001-10-24
ATE202552T1 (de) 2001-07-15
DZ2012A1 (fr) 2002-07-21
HK1016964A1 (en) 1999-11-12
MX9707596A (es) 1998-06-30
ES2160240T3 (es) 2001-11-01
DE69613567T2 (de) 2002-04-18
MA23837A1 (fr) 1996-12-31
SK282900B6 (sk) 2003-01-09
DE69613567D1 (de) 2001-08-02
KR19980703562A (ko) 1998-11-05
EP0819113B1 (en) 2001-06-27
GR3036466T3 (en) 2001-11-30
AU721045B2 (en) 2000-06-22
IL117629A0 (en) 1996-07-23
EE03437B1 (et) 2001-06-15
EA199700287A1 (ru) 1998-04-30
SK132597A3 (en) 1998-09-09
CA2215166A1 (en) 1996-10-10
BG101929A (en) 1998-04-30
EE9700235A (et) 1998-04-15
PL184121B1 (pl) 2002-09-30
BG63384B1 (bg) 2001-12-29
IS1919B (is) 2004-03-15
HRP960156A2 (en) 1997-10-31
HRP960156B1 (en) 2002-04-30
PT819113E (pt) 2001-10-30
CO4700431A1 (es) 1998-12-29
SA96160739B1 (ar) 2005-10-15
IL117629A (en) 2000-08-13
YU21096A (sh) 1999-03-04
TW381073B (en) 2000-02-01
CZ309897A3 (cs) 1998-12-16
NO974569D0 (no) 1997-10-02

Similar Documents

Publication Publication Date Title
FI962249A7 (fi) Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten
FI973292A7 (fi) Substituoituja isoksatsoleja tulehduksen hoitamiseksi
IL121170A0 (en) Compositions for the treatment of dermatological disorders
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
NO982172D0 (no) Anvendelse av epinastin for behandling av smerter
NO963785D0 (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
NO961483L (no) Fremgangsmåte for behandling av oljeholdig formasjon
NO306977B1 (no) Anvendelse av tienol[1,5]benzodiazepin for behandling av tilstander i mave/tarmkanalen
DE69737402D1 (de) Vorrichtung zur Behandlung von neurodegenerativen Störungen
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
NO996483D0 (no) Imidazopyrimidiner og imidazopyridiner for behandling av neurologiske forstyrrelser
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
NO20010456L (no) Triazolopyridiner for behandling av trombose lidelser
FI973023L (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
NO974569D0 (no) Benzamider for behandling av neurodegenerative forstyrrelser
FI942400L (fi) Lääkeaine hermosairauksia vastaan
NO973081D0 (no) Fremgangmåte for behandling av kroniske progressive vaskulære sykdommer
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
NO982562D0 (no) Sammensetning for behandling av smerte
BR9608595A (pt) Utilização de n-cicloexil benzamidas para o tratamento de aglições intestinais
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
NO953089L (no) Steroider for behandling av klimakterieplager